Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort

Author:

Ruscitti Piero1,Pantano Ilenia2,Cataldi Giulia1,Gentile Martina1,Arrigoni Francesco1,Riccio Luca2,Marrone Sabrina2,Mauro Daniele2,Ursini Francesco34ORCID,Esposito Maria1,Barile Antonio1,Fargnoli Maria Concetta1,Giacomelli Roberto56,Ciccia Francesco2ORCID,Cipriani Paola1

Affiliation:

1. Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila , L'Aquila, Italy

2. Department of Precision Medicine, School of Medicine and Surgery, University della Campania “Luigi Vanvitelli” , Naples, Italy

3. Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli , Bologna, Italy

4. Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna , Bologna, Italy

5. Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome “Campus Bio-Medico” , Rome, Italy

6. Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Universitario Campus Bio-Medico , Rome, Italy

Abstract

Abstract Objective To evaluate the short-term effectiveness of guselkumab in patients with psoriatic arthritis (PsA) and suggestive features of axial involvement in a prospective ‘real-life’ multicentre cohort. Methods Between June 2022 and June 2023, PsA patients with axial involvement were evaluated if treated at least for 4 months with guselkumab. The effectiveness was evaluated by BASDAI, ASDAS, DAPSA, and achievement of BASDAI ≤ 4, also exploiting predictive factors. In a group of patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration. Results Sixty-seven patients with PsA and suggestive features of axial involvement (age 53.4 ± 11.2 years, male sex 26.9%) were treated with guselkumab. After 4 months, a significant reduction of BASDAI, ASDAS, and DAPSA was observed. A ΔBASDAI of −2.11 ± 0.43 was estimated assessing the mean difference values before and after guselkumab administration and 52.2% of patients reached a BASDAI ≤ 4. In 27 patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration. A reduction of 0.80 or larger in the sacroiliac joint lesion score was observed in the majority of patients (70.3%) based on MRI improvements, paralleling with the clinical response. No life-threatening side effects were recorded; 17.9% of patients reported minor adverse events mainly injection site reactions. Conclusions The short-term effectiveness of guselkumab in patients with PsA and suggestive features of axial involvement were shown. Although further studies are needed, our multicentre ‘real-life’ study may suggest the clinical usability of guselkumab in this context.

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3